<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883049</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-03797</org_study_id>
    <secondary_id>NCI-2011-03797</secondary_id>
    <secondary_id>CDR0000706370</secondary_id>
    <secondary_id>AALL1131</secondary_id>
    <secondary_id>COG-AALL1131</secondary_id>
    <secondary_id>S12-01254</secondary_id>
    <secondary_id>AALL1131</secondary_id>
    <secondary_id>AALL1131</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT02883049</nct_id>
    <nct_alias>NCT01406756</nct_alias>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations</brief_title>
  <official_title>A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies how well combination chemotherapy works in treating
      young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come
      back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase
      inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to
      stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
      or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and
      giving the drugs in different doses and in different combinations may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if the administration of post-Induction age-adjusted intrathecal triple
      therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose
      methotrexate (IMHDM) backbone will improve 5-year disease-free survival (DFS) of children
      with high-risk (HR) B-acute lymphoblastic leukemia (ALL) compared to age-adjusted intrathecal
      (IT) methotrexate (MTX).

      II. To determine, in a randomized fashion, if the cyclophosphamide + etoposide containing
      regimen (Experimental Arm 1) will improve the 4-year DFS of children, adolescents, and young
      adults with very high-risk (VHR) B-ALL compared to a modified MBFM-IMHDM regimen that
      contains a second IM (Control Arm).

      SECONDARY OBJECTIVES:

      I. To determine the toxicity and tolerability of post-Induction age-adjusted ITT compared to
      age-adjusted IT MTX in children with HR B-ALL.

      II. To determine the toxicity and tolerability of Experimental Arm 1 compared to the Control
      Arm in children, adolescents, and young adults with VHR B-ALL.

      III. To determine whether a single-arm, modified Induction with limited anthracycline
      exposure and post-Induction therapy regimen with MBFM-IMIDM and reduced vincristine
      (vincristine sulfate)/steroid pulse frequency and enhanced supportive care in children with
      Down syndrome (DS) and HR B-ALL will result in a &gt;= 65% 5-year DFS and &lt; 10% Induction
      mortality.

      IV. To describe the outcomes for children and young adults with Ph-like B-ALL and a predicted
      TKI-sensitive mutation treated with dasatinib plus MBFM-IMHDM.

      V. To determine the toxicity and tolerability of MBFM-IMIDM in children with DS and HR B-ALL.

      VI. To estimate overall survival (OS) rates both overall and by regimen a) for HR B-ALL and
      b) VHR B-ALL patients.

      VII. To determine the incidence of osteonecrosis (ON), defined by magnetic resonance (MR)
      imaging, and to characterize the natural history of clinically silent ON in children,
      adolescents, and young adults 10 years of age and greater and to assess the role of drugs
      (i.e., asparaginase and methotrexate) in addition to corticosteroids, in the risk for
      development of ON.

      VIII. To determine if the prevalence of cognitive deficits measured by CogState, in children
      (ages 6 to =&lt; 13 years) with HR- and VHR B-ALL at 1 year off therapy, is significantly higher
      than the normative population (&gt; 14%) in the following domains: working memory, executive
      function, visual motor, processing speed, and visual attention.

      TERTIARY OBJECTIVES:

      I. To determine if the reduction of minimal residual disease (MRD) from end-Induction to
      end-Consolidation is greater for children, adolescents, and young adults with VHR B-ALL
      receiving Experimental Arm 1 compared to the Control Arm.

      OUTLINE:

      INDUCTION THERAPY:

      Patients without Down syndrome receive induction chemotherapy comprising cytarabine
      intrathecally (IT) on day 1; vincristine sulfate intravenously (IV) over 1 minute on days 1,
      8, 15, and 22; daunorubicin hydrochloride IV over 1-15 minutes on days 1, 8, 15, and 22;
      dexamethasone orally (PO) or IV twice daily (BID) on days 1-14 (patients under 10 years old)
      or prednisone PO or IV BID on days 1-28 (patients at least 10 years old); pegaspargase IV
      over 1-2 hours on day 4; and methotrexate IT on days 8 and 29 for CNS1 and CNS2 (plus days 15
      and 22 for CNS3 patients). Treatment continues for 56 days in the absence of disease
      progression or unacceptable toxicity.

      CONSOLIDATION THERAPY: Patients are randomized to 1 of 2 treatment arms.

      ARM I HR B-ALL CONSOLIDATION (C): Patients receive consolidation therapy comprising
      cyclophosphamide IV over 30-60 minutes on days 1 and 29; cytarabine IV over 1-30 minutes or
      subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO once daily (QD) on
      days 1-14 and 29-42, methotrexate IT on days 1, 8, 15, and 22; vincristine sulfate IV over 1
      minute on days 15, 22, 43, and 50; and pegaspargase IV over 1-2 hours on days 15 and 43.
      Patients with continuing clinical evidence of testicular leukemia undergo radiotherapy (RT)
      QD, 5 days a week, for approximately 2Â½ weeks (12 fractions total). Treatment continues for
      56 days in the absence of disease progression or unacceptable toxicity.

      ARM II HR B-ALL C: Patients receive Consolidation therapy as in Arm I HR B-ALL C. Patients
      also receive ITT comprising methotrexate, hydrocortisone sodium succinate, and cytarabine on
      days 1, 8, 15, and 22. Patients with testicular leukemia also undergo RT as in Arm I HR B-ALL
      C.

      INTERIM MAINTENANCE THERAPY:

      ARM I HR B-ALL INTERIM MAINTENANCE (IM): Patients receive IM therapy comprising vincristine
      sulfate IV over 1 minute on days 1, 15, 29, and 43; high-dose methotrexate IV over 24 hours
      on days 1, 15, 29, and 43; leucovorin calcium PO or IV on days 3-4, 17-18, 31-32, and 45-46;
      methotrexate IT on days 1 and 29; and mercaptopurine PO on days 1-56. Treatment continues for
      63 days in the absence of disease progression or unacceptable toxicity.

      ARM II HR B-ALL IM: Patients receive ITT on days 1 and 29 and IM therapy as in Arm I HR-ALL
      IM. Treatment continues for 63 days in the absence of disease progression or unacceptable
      toxicity.

      DELAYED INTENSIFICATION THERAPY:

      ARM I HR B-ALL DELAYED INTENSIFICATION (DI): Patients receive DI therapy comprising
      vincristine sulfate IV over 1 hour on days 1, 8, 15, 43, and 50; dexamethasone PO or IV BID
      on days 1-7 and 15-21; doxorubicin hydrochloride IV over 1-60 minutes on days 1, 8, and 15;
      methotrexate IT on days 1, 29, and 36; pegaspargase IV over 1-2 hours on days 4 and 43;
      cyclophosphamide IV over 30-60 minutes on day 29; cytarabine IV over 1-30 minutes or SC on
      days 29-32 and 36-39; and thioguanine PO QD on days 29-42. Treatment continues for 56 days in
      the absence of disease progression or unacceptable toxicity.

      ARM II HR B-ALL DI: Patients receive ITT on days 1, 29, and 36 and DI therapy as in Arm I HR
      B-ALL DI.

      MAINTENANCE (M) THERAPY:

      ARM I HR B-ALL M: Patients receive maintenance therapy comprising vincristine sulfate IV over
      1 minute on days 1, 29, and 57; methotrexate IT on day 1 (also day 29 of courses 1-4);
      prednisone PO BID on days 1-5, 29-33 (may receive methylprednisolone IV if PO is not
      tolerated), and 57-61; mercaptopurine PO QD on days 1-84; and methotrexate PO on days 8, 15,
      22, 29, 36, 43, 50, 57, 64, 71, and 78. Treatment repeats every 12 weeks for 2 years
      (females) or 3 years (males) in the absence of disease progression or unacceptable toxicity.

      ARM II HR B-ALL M: Patients receive ITT on day 1 (also day 29 of courses 1-4) and maintenance
      therapy as in Arm I HR B-ALL M. Treatment repeats every 12 weeks for 2 years (females) or 3
      years (males) in the absence of disease progression or unacceptable toxicity.

      VERY HIGH-RISK B-ALL: Patients are randomized to 1 of 3 treatment arms.

      CONSOLIDATION THERAPY PART I: In all arms, patients receive cyclophosphamide IV over 30-60
      minutes on day 1; cytarabine IV or SC on days 1-4 and 8-11; mercaptopurine PO QD on days
      1-14; methotrexate IT on days 1, 8, 15, and 22 (days 1 and 8 only for CNS3 patients);
      vincristine sulfate IV over 1 minute on days 15 and 22; and pegaspargase IV over 1-2 hours on
      day 15. Patients with continuing clinical evidence of testicular leukemia undergo RT QD, 5
      days a week, for approximately 2Â½ weeks (12 fractions total). Treatment continues for 28 days
      in the absence of disease progression or unacceptable toxicity.

      CONSOLIDATION THERAPY PART II:

      ARM A VHR B-ALL C (CONTROL ARM): Patients receive consolidation therapy comprising
      cyclophosphamide IV over 30-60 minutes on day 29; cytarabine IV over 1-30 minutes or SC on
      days 29-32 and 36-39; mercaptopurine PO QD on days 29-42; vincristine sulfate IV over 1
      minute on days 43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment continues
      for 28 days in the absence of disease progression or unacceptable toxicity.

      ARM B VHR B-ALL C (EXPERIMENTAL ARM): Patients receive consolidation therapy comprising
      cyclophosphamide IV over 15-30 minutes on days 29-33; etoposide IV over 60-120 minutes on
      days 29-33; vincristine sulfate IV over 1 minute on days 43 and 50; and pegaspargase IV over
      1-2 hours on day 43. Treatment continues for 28 days in the absence of disease progression or
      unacceptable toxicity. (CLOSED 02/15/2017)

      ARM C VHR B-ALL C: Patients receive clofarabine IV over 2 hours on days 29-33 and
      consolidation therapy as in Arm B VHR B-ALL C. (CLOSED 9/12/2014)

      INTERIM MAINTENANCE I: In all arms, patients receive vincristine sulfate IV over 1 minute on
      days 1, 15, 29, and 43; high-dose methotrexate IV over 24 hours on days 1, 15, 29, and 43;
      leucovorin calcium PO or IV on days 3-4, 17-18, 31-32, and 45-46; mercaptopurine PO QD on
      days 1-56; and methotrexate IT on days 1 and 29. Treatment continues for 63 days in the
      absence of disease progression or unacceptable toxicity.

      DELAYED INTENSIFICATION PART I: In all arms, patients receive vincristine sulfate IV over 1
      minute on days 1, 8, and 15; dexamethasone PO or IV BID on days 1-7 and 15-21; doxorubicin
      hydrochloride IV over 1-60 minutes on days 1, 8, and 15; methotrexate IT on day 1; and
      pegaspargase IV over 1-2 hours on day 4. Treatment continues for 28 days in the absence of
      disease progression or unacceptable toxicity.

      DELAYED INTENSIFICATION PART II:

      ARM A VHR B-ALL DI (CONTROL ARM): Patients receive DI therapy comprising cyclophosphamide IV
      over 30-60 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39;
      thioguanine PO QD on days 29-42; methotrexate IT on days 29 and 36; vincristine sulfate IV
      over 1 minute on days 43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment
      continues for 28 days in the absence of disease progression or unacceptable toxicity.

      ARM B VHR B-ALL DI (EXPERIMENTAL ARM): Patients receive DI therapy comprising
      cyclophosphamide IV over 15-30 minutes on days 29-33; etoposide IV over 60-120 minutes on
      days 29-33; methotrexate IT on days 29 and 36; vincristine sulfate IV over 1 minute on days
      43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment continues for 28 days in
      the absence of disease progression or unacceptable toxicity.

      ARM C VHR B-ALL DI: Patients receive clofarabine IV over 2 hours on days 29-33 and DI therapy
      as in Arm II B VHR B-ALL DI. (Closed as of 9/12/2014)

      INTERIM MAINTENANCE II: In all arms, patients receive vincristine sulfate IV over 1 minute
      and methotrexate IV over 2-5 minutes (undiluted) or 10-15 minutes (diluted) on days 1, 11,
      21, 31, and 41; pegaspargase IV over 1-2 hours on days 2 and 22; and methotrexate IT on days
      1 and 31. Treatment continues for 56 days in the absence of disease progression or
      unacceptable toxicity.

      MAINENTANCE THERAPY: Patients with CNS3 disease at diagnosis undergo RT QD over 4 weeks (10
      fractions total). In all arms, patients receive vincristine sulfate IV over 1 minute on days
      1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61 (may receive
      methylprednisolone IV if PO is not tolerated); methotrexate PO on days 8, 15, 22, 29, 36, 43,
      50, 57, 64, 71, and 78 (except on methotrexate IT days); mercaptopurine PO QD on days 1-84;
      methotrexate IT on day 1 (also day 29 of courses 1 and 2 for CNS patients who did not undergo
      RT). Treatment repeats every 12 weeks for 2 years (females) or 3 years (males) in the absence
      of disease progression or unacceptable toxicities.

      INDUCTION THERAPY: All patients receive cytarabine IT on day 1; vincristine sulfate IV over 1
      minute on days 1 and 8, dexamethasone PO or IV BID (patients under 10 years old) or
      prednisone PO BID (patients at least 10 years old) on days 1-14 (may receive
      methylprednisolone IV if PO is not tolerated), pegaspargase IV over 1-2 hours on day 4;
      methotrexate IT on day 8; and leucovorin calcium PO on days 10-11. Treatment continues for 14
      days in the absence of disease progression or unacceptable toxicity.

      Rapid early responders (RER): Patients receive induction therapy comprising vincristine
      sulfate IV over 1 minute on days 15 and 22; dexamethasone PO BID or prednisone PO BID on days
      15-28; methotrexate IT on day 29 (also days 15 and 22 for CNS3 patients); and leucovorin
      calcium PO on days 31-32 (also days 17-18 and 24-25 for CNS3 patients). Treatment continues
      for 14 days in the absence of disease progression or unacceptable toxicity.

      Slow early responders (SER): Patients receive daunorubicin hydrochloride IV over 1-15 minutes
      on day 15 and Induction therapy as RER patients. Treatment continues for 14 days in the
      absence of disease progression or unacceptable toxicity.

      CONSOLIDATION THERAPY: All patients receive cyclophosphamide IV over 30-60 minutes on days 1
      and 29; cytarabine IV over 1-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39;
      mercaptopurine PO QD on days 1-14 and 29-42; vincristine sulfate IV over 1 minute on days 15,
      22, 43, and 50; pegaspargase IV over 1-2 hours on days 15 and 43; methotrexate IT on days 1,
      8, 15, and 22 (days 1 and 8 only for CNS3 patients); and leucovorin calcium PO on days 3-4,
      10-11, 17-18, and 24-25. Patients with continuing clinical evidence of testicular leukemia
      undergo RT QD, 5 days a week, for approximately 2Â½ weeks (12 fractions total). Treatment
      continues for 56 days in the absence of disease progression or unacceptable toxicity.

      INTERIM MAINTENANCE THERAPY: Patients receive vincristine sulfate IV over 1 minute on days 1,
      15, 29, and 43; intermediate dose methotrexate IV over 24 hours on days 1, 15, 29, and 43;
      leucovorin calcium PO or IV on days 2-3, 17-18, 31-32, and 45-46; mercaptopurine PO QD on
      days 1-56; and methotrexate IT on days 1 and 29. Treatment continues for 63 days in the
      absence of disease progression or unacceptable toxicity.

      DELAYED INTENSIFICATION THERAPY: Patients receive vincristine sulfate IV over 1 minute on
      days 1, 8, 15, 43, and 50; dexamethasone PO BID or IV on days 1-7 and 15-21; doxorubicin
      hydrochloride IV over 1-60 minutes on days 1, 8, and 15; pegaspargase IV over 1-2 hours on
      days 4 and 43; cyclophosphamide IV over 30-60 minutes on day 29; thioguanine PO QD on days
      29-42; cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39; methotrexate IT on days
      1, 29, and 36; and leucovorin calcium PO on days 3-4, 31-32 and 38-39.

      MAINTENANCE THERAPY: Patients with CNS3 disease undergo RT QD, 5 days a week, for 2 weeks (10
      fractions total). Patients receive vincristine sulfate IV over 1 minute on day 1; prednisone
      PO BID or IV on days 1-5 (may receive methylprednisolone IV if PO not tolerated);
      methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO QD
      on days 1-84; and methotrexate IT on day 1 (also day 29 of courses 1-4 for CNS3 patients who
      did not undergo RT). Treatment repeats every 12 weeks for 2 years in the absence of disease
      progression or unacceptable toxicity.

      PH-LIKE PREDICTED TKI-SENSITIVE KINASE MUTATION:

      CONSOLIDATION THERAPY: Patients receive dasatinib PO QD on days 1-56, cyclophosphamide IV
      over 30-60 minutes on days 1 and 29, cytarabine IV over 1-30 minutes or SC on days 1-4, 8-11,
      29-32 and 36-39, mercaptopurine PO on days 1-14 and 29-42, methotrexate IT on days 1, 8, 15
      and 22, vincristine sulfate IV over 1 minute on days 15, 22, 43 and 50, and pegaspargase IV
      over 1-2 hours on days 15 and 43.

      INTERIM MAINTENANCE THERAPY: Patients receive dasatinib PO QD on days 1-63, vincristine
      sulfate IV over 1 minute on days 1, 15, 29, and 43, high dose methotrexate IV over 24 hours
      on days 1, 15, 29, and 43, leucovorin calcium PO or IV on days 3-4, 17-18, 31-32, and 45-46,
      methotrexate IT on days 1 and 29, and mercaptopurine PO on days 1-56.

      DELAYED INTENSIFICATION THERAPY: Patients receive dasatinib PO QD on days 1-56, vincristine
      sulfate IV over 1 minute on days 1, 8, 15, 43, and 50, dexamethasone PO or IV on days 1-7 and
      15-21, doxorubicin hydrochloride IV over 1-15 minutes on days 1, 8 and 15, methotrexate IT on
      days 1, 29 and 36, pegaspargase IV over 1-2 hours on days 4 and 43, cyclophosphamide IV over
      30-60 minutes day 29, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, and
      thioguanine PO on days 29-42.

      INTERIM MAINTENANCE THERAPY II: Patients dasatinib PO QD on days 1-56, vincristine sulfate IV
      over 1 minute days 1, 11, 21, 31, and 41, methotrexate IV over up to 15 minutes on days 1,
      11, 21, 31 and 41, methotrexate IT on days 1 and 31, and pegaspargase IV over 1-2 hours days
      2 and 22.

      MAINTENANCE THERAPY: Patients receive dasatinib PO QD on days 1-84, vincristine sulfate IV
      over 1 minute on days 1, 29 and 57, prednisone PO BID or IV on days 1-5, 29-33 and 57-61,
      methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71 and 78 (omit on days when MTX
      [IT] is given), mercaptopurine PO on days 1-84, methotrexate IT on day 1 (also day 29 of
      course 1 and 2, for patients who did not receive CNS radiation). Treatment repeats every 12
      weeks for 2 years in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2012</start_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of disease-free survival (DFS) of children with high-risk (HR) B-acute lymphoblastic leukemia (ALL)</measure>
    <time_frame>At 5 years</time_frame>
    <description>DFS of children with HR B-acute ALL receiving post-induction age adjusted intrathecal triple therapy (ITT) on an Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone will be compared to age adjusted intrathecal (IT) methotrexate (MTX). Compared using 2-sided log rank test, alpha = 5%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS of children, adolescents, and young adults with very high-risk (VHR) B-ALL between arms</measure>
    <time_frame>At 4 years</time_frame>
    <description>DFS of children, adolescents, and young adults with VHR B-ALL will be compared in all arms using 1-sided log rank test, alpha 0.025.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Graded using the version 5.0 Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and tolerability of Experimental arm and Control arm in patients with VHR B-ALL</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Graded using the version 5.0 CTCAE of the NCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of greater than or equal to 65% of 5-year DFS and less than 10% induction mortality in patients with Down syndrome (DS) and HR B-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children and young adults with Ph-like B-ALL and a predicted tyrosine kinase inhibitor (TKI)-sensitive mutation treated with dasatinib plus MBFM-IMHDM</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Graded using the version 5.0 CTCAE of the NCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD less than or equal to 0.01% upon recovery from consolidation</measure>
    <time_frame>Week 13-14</time_frame>
    <description>Compared between control vs experimental arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate for HR B-ALL patients</measure>
    <time_frame>At 5 years</time_frame>
    <description>Compared informally between arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate for VHR B-ALL patients</measure>
    <time_frame>At 4 years</time_frame>
    <description>Compared informally between arms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the minimal residual disease (MRD) from end-Induction to end-Consoldiation</measure>
    <time_frame>Baseline to up to 10 years</time_frame>
    <description>Whether the reduction of MRD from end-Induction to end-Consolidation is greater for children, adolescents, and young adults with VHR B-ALL receiving Experimental Arms 1 and/or 2 compared to the Control Arm will be determined.</description>
  </other_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">5956</enrollment>
  <condition>B Acute Lymphoblastic Leukemia</condition>
  <condition>Central Nervous System Leukemia</condition>
  <condition>Ph-Like Acute Lymphoblastic Leukemia</condition>
  <condition>Testicular Leukemia</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive consolidation therapy comprising cyclophosphamide IV over 30-60 minutes on day 29; cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39; mercaptopurine PO QD on days 29-42; vincristine sulfate IV over 1 minute on days 43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive DI therapy comprising cyclophosphamide IV over 30-60 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; thioguanine PO QD on days 29-42; methotrexate IT on days 29 and 36; vincristine sulfate IV over 1 minute on days 43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (VHR B-ALL C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive consolidation therapy comprising cyclophosphamide IV over 15-30 minutes on days 29-33; etoposide IV over 60-120 minutes on days 29-33; vincristine sulfate IV over 1 minute on days 43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive DI therapy comprising cyclophosphamide IV over 15-30 minutes on days 29-33; etoposide IV over 60-120 minutes on days 29-33; methotrexate IT on days 29 and 36; vincristine sulfate IV over 1 minute on days 43 and 50; and pegaspargase IV over 1-2 hours on day 43. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive clofarabine IV over 2 hours on days 29-33 and consolidation therapy as in Arm B VHR B-ALL C. (Closed as of 9/12/2014)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive clofarabine IV over 2 hours on days 29-33 and DI therapy as in Arm II B VHR B-ALL DI. (Closed as of 9/12/2014)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Consolidation therapy comprising cyclophosphamide IV over 30-60 minutes on days 1 and 29; cytarabine IV over 1-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO QD on days 1-14 and 29-42, methotrexate IT on days 1, 8, 15, and 22; vincristine sulfate IV over 1 minute on days 15, 22, 43, and 50; and pegaspargase IV over 1-2 hours on days 15 and 43. Patients with continuing clinical evidence of testicular leukemia undergo RT QD, 5 days a week, for approximately 2Â½ weeks (12 fractions total). Treatment continues for 56 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive DI therapy comprising vincristine sulfate IV over 1 hour on days 1, 8, 15, 43, and 50; dexamethasone PO or IV BID on days 1-7 and 15-21; doxorubicin hydrochloride IV over 1-60 minutes on days 1, 8, and 15; methotrexate IT on days 1, 29, and 36; pegaspargase IV over 1-2 hours on days 4 and 43; cyclophosphamide IV over 30-60 minutes on day 29; cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO QD on days 29-42. Treatment continues for 56 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I (HR B-ALL IM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive IM therapy comprising vincristine sulfate IV over 1 minute on days 1, 15, 29, and 43; high-dose methotrexate IV over 24 hours on days 1, 15, 29, and 43; leucovorin calcium PO or IV on days 3-4, 17-18, 31-32, and 45-46; methotrexate IT on days 1 and 29; and mercaptopurine PO on days 1-56. Treatment continues for 63 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I (HR B-ALL M)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive maintenance therapy comprising vincristine sulfate IV over 1 minute on days 1, 29, and 57; methotrexate IT on day 1 (also day 29 of courses 1-4); prednisone PO BID on days 1-5, 29-33 (may receive methylprednisolone IV if PO is not tolerated), and 57-61; mercaptopurine PO QD on days 1-84; and methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Treatment repeats every 12 weeks for 2 years (females) or 3 years (males) in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Consolidation therapy as patients in Arm I HR B-ALL C. Patients also receive ITT comprising methotrexate, hydrocortisone sodium succinate, and cytarabine on days 1, 8, 15, and 22. Patients with testicular leukemia also undergo RT as in Arm I HR B-ALL C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ITT on days 1, 29, and 36 and DI therapy as in Arm I HR B-ALL DI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (HR B-ALL IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ITT on days 1 and 29 and IM therapy as in Arm I HR B-ALL IM. Treatment continues for 63 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ITT on day 1 (also day 29 of courses 1-4) and maintenance therapy as in Arm I HR B-ALL M. Treatment repeats every 12 weeks for 2 years (females) or 3 years (males) in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib PO QD on days 1-56, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine IV over 1-30 minutes or SC on days 1-4, 8-11, 29-32 and 36-39, mercaptopurine PO on days 1-14 and 29-42, methotrexate IT on days 1, 8, 15 and 22, vincristine IV over 1 minute on days 15, 22, 43 and 50, and pegaspargase IV over 1-2 hours on days 15 and 43.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IT, IV, or SC</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>PO or IV</description>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Sodium Succinate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <other_name>(11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt</other_name>
    <other_name>A-Hydrocort</other_name>
    <other_name>Buccalsone</other_name>
    <other_name>Corlan</other_name>
    <other_name>Cortisol sodium succinate</other_name>
    <other_name>Cortop</other_name>
    <other_name>Efcortelan</other_name>
    <other_name>Emergent-EZ</other_name>
    <other_name>Flebocortid</other_name>
    <other_name>Hidroc Clora</other_name>
    <other_name>Hycorace</other_name>
    <other_name>Hydro-Adreson</other_name>
    <other_name>Hydrocort</other_name>
    <other_name>Hydrocortisone 21-Sodium Succinate</other_name>
    <other_name>Hydrocortisone Na Succinate</other_name>
    <other_name>Kinogen</other_name>
    <other_name>Nordicort</other_name>
    <other_name>Nositrol</other_name>
    <other_name>Sinsurrene</other_name>
    <other_name>Sodium hydrocortisone succinate</other_name>
    <other_name>Solu-Cortef</other_name>
    <other_name>Solu-Glyc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm I (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>BW 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT and IV</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>L-Asparaginase with Polyethylene Glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase (Enzon - Kyowa Hakko)</other_name>
    <other_name>PEGLA</other_name>
    <other_name>Polyethylene Glycol L-Asparaginase</other_name>
    <other_name>Polyethylene Glycol-L-Asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Arm I (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>irradiation</other_name>
    <other_name>RADIATION</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>2-Amino 6MP</other_name>
    <other_name>2-Amino-1,7-dihydro-6H-purine-6-thione</other_name>
    <other_name>2-Amino-6-mercaptopurine</other_name>
    <other_name>2-Amino-6-purinethiol</other_name>
    <other_name>2-Aminopurin-6-thiol</other_name>
    <other_name>2-Aminopurine-6(1H)-thione</other_name>
    <other_name>2-Aminopurine-6-thiol</other_name>
    <other_name>2-Mercapto-6-aminopurine</other_name>
    <other_name>6-Amino-2-mercaptopurine</other_name>
    <other_name>6-Mercapto-2-aminopurine</other_name>
    <other_name>6-Mercaptoguanine</other_name>
    <other_name>6-TG</other_name>
    <other_name>6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)</other_name>
    <other_name>BW 5071</other_name>
    <other_name>Lanvis</other_name>
    <other_name>Tabloid</other_name>
    <other_name>Tioguanin</other_name>
    <other_name>Tioguanine</other_name>
    <other_name>Wellcome U3B</other_name>
    <other_name>WR-1141</other_name>
    <other_name>X 27</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL C)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL IM)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm I (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm II (HR B-ALL M)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL C)</arm_group_label>
    <arm_group_label>Arm A (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm B (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Arm C (VHR B-ALL DI)</arm_group_label>
    <arm_group_label>Ph-like TKI-sensitive kinase mutation</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be enrolled on AALL08B1 or APEC14B1 (if available for ALL patients)
             prior to enrollment on AALL1131

          -  White Blood Cell Count (WBC) Criteria

               -  Age 1-9.99 years: WBC &gt;= 50 000/uL

               -  Age 10-30.99 years: Any WBC

               -  Age 1-30.99 years: Any WBC with:

                    -  Testicular leukemia

                    -  CNS leukemia (CNS3)

                    -  Steroid pretreatment

          -  Patients must have newly diagnosed B lymphoblastic leukemia (2008 World Health
             Organization [WHO] classification) (also termed B-precursor acute lymphoblastic
             leukemia); patients with Down syndrome are also eligible

          -  Organ function requirements for patients with Ph-like ALL and a predicted
             TKI-sensitive mutation: patients identified as Ph-like with a TKI-sensitive kinase
             mutation must have assessment of organ function performed within 3 days of study entry
             onto the dasatinib arm of AALL1131

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt; 70mL/min/1.73
             m^2 or a serum creatinine based on age/gender as follows:

               -  Age: Maximum Serum Creatinine (mg/dL)

               -  1 to &lt; 6 months: 0.4 (male) 0.4 (female)

               -  6 months to &lt; 1 year: 0.5 (male) 0.5 (female)

               -  1 to &lt; 2 years: 0.6 (male) 0.6 (female)

               -  2 &lt; 6 years: 0.8 (male) 0.8 (female)

               -  6 to &lt; 10 years: 1.0 (male) 1.0 (female)

               -  10 to &lt; 13 years: 1.2 (male) 1.2 (female)

               -  13 to &lt; 16 years: 1.5 (male) 1.4 (female)

               -  &gt; 16 years: 1.7 (male) 1.4 (female)

          -  Direct bilirubin =&lt; 3 x upper limit of normal (ULN) for age, and

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 10 x
             upper limit of normal (ULN) for age

          -  Shortening fraction &gt;= 27% by echocardiogram, or ejection fraction &gt;= 50% by gated
             radionuclide study

               -  Patients must have an electrocardiogram (EKG) fewer than 6 days prior to
                  enrollment on the dasatinib arm; patients who have had cardiac assessments by
                  echocardiogram or radionuclide scan at the beginning of induction do not need to
                  have these repeated prior to study entry; correct QT interval (QTc) &lt; 450 msec on
                  baseline electrocardiogram as measured by the Frederica or Bazett formula

               -  No major conduction abnormality (unless a cardiac pacemaker is present)

          -  No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry &gt; 94% at
             sea level if there is clinical indication for determination

          -  Patients with seizure disorder may be enrolled if on anticonvulsants and well
             controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine,
             phenytoin, primidone, phenobarbital) should be avoided

          -  Eligibility criteria for the Longitudinal, Computerized Assessment of Neurocognitive
             Functioning study

               -  Patients must be aged 6 to 13 years at time of B-ALL diagnosis, enrolled on
                  AALL1131

               -  Patients must be English-, French- or Spanish-speaking (languages in which the
                  assessment is available)

               -  Patients must have no known history of neurodevelopmental disorder prior to
                  diagnosis of B-ALL (e.g., Down syndrome, Fragile X, William's Syndrome, mental
                  retardation)

               -  Patients must have no significant visual impairment that would prevent computer
                  use and recognition of the visual test stimuli

          -  Eligibility criteria for the National Cancer Institute (NCI) standard risk patients
             from AALL0932 enrolling on this study at the end of Induction

          -  Patients enrolled on AALL0932, without Down syndrome, meeting the following criteria
             will NOT be eligible to continue on AALL0932 but WILL BE eligible to enroll on the HR
             B-ALL stratum of this study at the end of Induction:

               -  Without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4+10), with day
                  8 peripheral blood (PB) minimal residual disease (MRD) &gt;= 1% and day 29 BM MRD &lt;
                  0.01%

               -  With favorable cytogenetics (ETV6-RUNX1 or double trisomies 4+10), with any day 8
                  PB MRD and day 29 bone marrow (BM) MRD &gt;= 0.01%

               -  Both NCI standard risk (SR) and HR patients without Down syndrome and with
                  testicular disease at diagnosis, who do not meet other VHR criteria, will be
                  eligible for the HR stratum

          -  Effective Amendment 6, patients enrolled on AALL0932, without Down syndrome, meeting
             the following criteria will NOT be eligible to continue on AALL0932 or the VHR stratum
             of AALL1131:

               -  Intrachromosomal amplification of chromosome 21 (iAMP21)

               -  Mixed-lineage leukemia (MLL) rearrangement

               -  Hypodiploidy (n &lt; 44 chromosomes and/or a deoxyribonucleic acid [DNA] index &lt;
                  0.81)

               -  Induction failure (M3 BM at day 29)

               -  Without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4+10), with day
                  29 BM MRD &gt;= 0.01%

          -  Patients enrolled on AALL0932, with Down syndrome, meeting the following criteria will
             NOT be eligible to continue on AALL0932 but WILL BE eligible to enroll on the DS HR
             B-ALL stratum of this study at the end of Induction:

               -  Day 29 MRD &gt;= 0.01%

               -  MLL rearrangement

               -  Hypodiploidy (n &lt; 45 chromosomes and/or DNA index &lt; 0.81)

          -  DS HR B-ALL patients initially enrolled on AALL0932 or this study who have Induction
             failure (M3 BM day 29) or Philadelphia chromosome (BCR-ABL1) will not be eligible for
             post-Induction therapy on either trial (AALL0932 or AALL1131)

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and NCI requirements for human
             studies must be met

        Exclusion Criteria:

          -  With the exception of steroid pretreatment or the administration of intrathecal
             cytarabine, patients must not have received any prior cytotoxic chemotherapy for
             either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation
             of protocol therapy on AALL1131; patients cannot have secondary B-ALL that developed
             after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving
             prior steroid therapy may be eligible for AALL1131

          -  Patients with BCR-ABL1 fusion are not eligible for post-induction therapy on this
             study but may be eligible to enroll in a successor Children's Oncology Group (COG)
             Philadelphia positive (Ph+) ALL trial by day 15 Induction

          -  DS HR B-ALL patients with Induction failure or BCR-ABL1

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible unless they have agreed not to breastfeed their
             infant

          -  Female patients of childbearing potential are not eligible unless a negative pregnancy
             test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Burke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa T. Reddy</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Alyssa T. Reddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia L. Wilson</last_name>
      <phone>251-665-8000</phone>
    </contact>
    <investigator>
      <last_name>Felicia L. Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda J. Wittman</last_name>
      <phone>907-212-6871</phone>
      <email>AKPAMC.OncologyResearchSupport@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brenda J. Wittman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardon Children's Medical Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erlyn C. Smith</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Erlyn C. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Boklan</last_name>
      <phone>602-546-0920</phone>
    </contact>
    <investigator>
      <last_name>Jessica Boklan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Medical Center-University Campus</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa M. Kopp</last_name>
      <phone>520-626-9008</phone>
    </contact>
    <investigator>
      <last_name>Lisa M. Kopp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L. Becton</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>David L. Becton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M. Cooper</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Robert M. Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna B. Pawlowska</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Anna B. Pawlowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Kheradpour</last_name>
      <phone>909-558-3375</phone>
    </contact>
    <investigator>
      <last_name>Albert Kheradpour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller Children's and Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela H. Kempert</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Pamela H. Kempert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Mascarenhas</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Leo Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fataneh (Fae) Majlessipour</last_name>
      <phone>310-423-8965</phone>
    </contact>
    <investigator>
      <last_name>Fataneh (Fae) Majlessipour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William A. May</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>William A. May</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636-8762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vonda L. Crouse</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Vonda L. Crouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla B. Golden</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Carla B. Golden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven K. Bergstrom</last_name>
      <phone>510-891-3400</phone>
    </contact>
    <investigator>
      <last_name>Steven K. Bergstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa M. Rubin</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Elyssa M. Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri L. Spunt</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Sheri L. Spunt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yung S. Yim</last_name>
      <phone>415-209-2686</phone>
      <email>bernicl@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Yung S. Yim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Michael S. Balagtas</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Jay Michael S. Balagtas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William D. Roberts</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>William D. Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center -San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelton A. Viola</last_name>
      <phone>619-532-8712</phone>
    </contact>
    <investigator>
      <last_name>Shelton A. Viola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mignon L. Loh</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Mignon L. Loh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J. Slomiany</last_name>
      <phone>805-682-7300</phone>
    </contact>
    <investigator>
      <last_name>David J. Slomiany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard H. Panosyan</last_name>
      <phone>310-222-3621</phone>
    </contact>
    <investigator>
      <last_name>Eduard H. Panosyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly W. Maloney</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Kelly W. Maloney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer J. Clark</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer J. Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S. Isakoff</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Michael S. Isakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina S. Kadan-Lottick</last_name>
      <phone>203-785-5702</phone>
    </contact>
    <investigator>
      <last_name>Nina S. Kadan-Lottick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi H. Caywood</last_name>
      <phone>302-651-6884</phone>
      <email>dperry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina E. Gonzalez</last_name>
      <phone>202-444-2223</phone>
    </contact>
    <investigator>
      <last_name>Corina E. Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey S. Dome</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey S. Dome</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector M. Rodriguez-Cortes</last_name>
      <phone>954-355-5346</phone>
    </contact>
    <investigator>
      <last_name>Hector M. Rodriguez-Cortes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad K. Salman</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Emad K. Salman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William B. Slayton</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>William B. Slayton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iftikhar Hanif</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Iftikhar Hanif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi H. Caywood</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio C. Barredo</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Julio C. Barredo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique A. Escalon</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Enrique A. Escalon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doured Daghistani</last_name>
      <phone>800-599-2456</phone>
      <email>cancerinfo@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Doured Daghistani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fouad M. Hajjar</last_name>
      <phone>407-303-2090</phone>
      <email>FH.Cancer.Research@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Fouad M. Hajjar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent F. Giusti</last_name>
      <phone>321-843-2584</phone>
    </contact>
    <investigator>
      <last_name>Vincent F. Giusti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi H. Caywood</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi H. Caywood</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter H. Shaw</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Peter H. Shaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan F. Rico</last_name>
      <phone>813-844-8113</phone>
      <email>hkourtellis@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Juan F. Rico</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark J. Mogul</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Mark J. Mogul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayana Gowda</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Narayana Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen Lew</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Glen Lew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen H. McDonough</last_name>
      <phone>706-721-1663</phone>
      <email>cancer@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Colleen H. McDonough</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. M. Johnston</last_name>
      <phone>912-350-8568</phone>
    </contact>
    <investigator>
      <last_name>J. M. Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wade T. Kyono</last_name>
      <phone>808-983-6090</phone>
    </contact>
    <investigator>
      <last_name>Wade T. Kyono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96859</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Chang</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Eugenia Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine R. Morgan</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Elaine R. Morgan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary L. Schmidt</last_name>
      <phone>312-355-3046</phone>
    </contact>
    <investigator>
      <last_name>Mary L. Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer L. McNeer</last_name>
      <phone>773-834-7424</phone>
    </contact>
    <investigator>
      <last_name>Jennifer L. McNeer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Suh</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Eugene Suh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca E. McFall</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca E. McFall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Park Ridge</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Y. Hu</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Caroline Y. Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro A. De Alarcon</last_name>
      <phone>888-226-4343</phone>
    </contact>
    <investigator>
      <last_name>Pedro A. De Alarcon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory P. Brandt</last_name>
      <phone>217-545-7929</phone>
    </contact>
    <investigator>
      <last_name>Gregory P. Brandt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamnesh R. Pradhan</last_name>
      <phone>800-248-1199</phone>
    </contact>
    <investigator>
      <last_name>Kamnesh R. Pradhan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy L. Woods-Swafford</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Wendy L. Woods-Swafford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariko Sato</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>Mariko Sato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars M. Wagner</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Lars M. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok B. Raj</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Ashok B. Raj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolie C. Yu</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Lolie C. Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Lotterman</last_name>
      <phone>504-842-3708</phone>
    </contact>
    <investigator>
      <last_name>Craig Lotterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine P. SantaCruz</last_name>
      <phone>207-973-4274</phone>
    </contact>
    <investigator>
      <last_name>Nadine P. SantaCruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric C. Larsen</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Eric C. Larsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa A. York</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Teresa A. York</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M. Fixler</last_name>
      <phone>410-601-6120</phone>
      <email>pridgely@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Jason M. Fixler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick A. Brown</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick A. Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Lieuw</last_name>
      <phone>301-319-2100</phone>
    </contact>
    <investigator>
      <last_name>Kenneth Lieuw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Kelly</last_name>
      <phone>617-636-5535</phone>
    </contact>
    <investigator>
      <last_name>Michael J. Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison M. Friedmann</last_name>
      <phone>877-726-5130</phone>
    </contact>
    <investigator>
      <last_name>Alison M. Friedmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna G. Luty</last_name>
      <phone>413-794-3565</phone>
      <email>tamara.wrenn@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Joanna G. Luty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher P. Keuker</last_name>
      <phone>508-856-3216</phone>
      <email>cancer.research@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher P. Keuker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond J. Hutchinson</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Raymond J. Hutchinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihong J. Wang</last_name>
      <phone>313-576-9363</phone>
    </contact>
    <investigator>
      <last_name>Zhihong J. Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Hospital and Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adonis N. Lorenzana</last_name>
      <phone>734-712-3671</phone>
    </contact>
    <investigator>
      <last_name>Adonis N. Lorenzana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renuka Gera</last_name>
      <phone>517-975-9547</phone>
    </contact>
    <investigator>
      <last_name>Renuka Gera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Dickens</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>David S. Dickens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina E. Elliott</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Katharina E. Elliott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Children's Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura K. Gowans</last_name>
      <phone>248-551-0360</phone>
    </contact>
    <investigator>
      <last_name>Laura K. Gowans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K. Richards</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Michael K. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter M. Gordon</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Peter M. Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilmarie Rodriguez</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Vilmarie Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail C. Megason</last_name>
      <phone>601-815-6700</phone>
    </contact>
    <investigator>
      <last_name>Gail C. Megason</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Regional</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara A. Gruner</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Barbara A. Gruner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith J. August</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Keith J. August</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William S. Ferguson</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>William S. Ferguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Hayashi</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Robert J. Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany G. Sleckman</last_name>
      <phone>314-251-6770</phone>
    </contact>
    <investigator>
      <last_name>Bethany G. Sleckman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnie Abromowitch</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minnie Abromowitch</last_name>
      <phone>402-559-6941</phone>
      <email>unmcrsa@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bernstein</last_name>
      <phone>702-384-0013</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Bernstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Center of Nevada II</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summerlin Hospital Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan K. Ikeda</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Chaffee</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Chaffee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burton E. Appel</last_name>
      <phone>201-996-2879</phone>
    </contact>
    <investigator>
      <last_name>Burton E. Appel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven L. Halpern</last_name>
      <phone>973-971-5900</phone>
    </contact>
    <investigator>
      <last_name>Steven L. Halpern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nibal A. Zaghloul</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Nibal A. Zaghloul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard A. Drachtman</last_name>
      <phone>732-235-8675</phone>
    </contact>
    <investigator>
      <last_name>Richard A. Drachtman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peri Kamalakar</last_name>
      <phone>973-926-7230</phone>
    </contact>
    <investigator>
      <last_name>Peri Kamalakar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary A. Bonilla</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Mary A. Bonilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koh B. Boayue</last_name>
      <phone>505-925-0366</phone>
      <email>LByatt@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Koh B. Boayue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth G. Lucas</last_name>
      <phone>518-262-5513</phone>
    </contact>
    <investigator>
      <last_name>Kenneth G. Lucas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter D. Cole</last_name>
      <phone>718-379-6862</phone>
      <email>sforde@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Peter D. Cole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara J. Bambach</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Barbara J. Bambach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark E. Weinblatt</last_name>
      <phone>516-663-3115</phone>
    </contact>
    <investigator>
      <last_name>Mark E. Weinblatt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Steven and Alexandra Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlene S. Redner</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Arlene S. Redner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon L. Gardner</last_name>
      <phone>212-263-4434</phone>
      <email>prmc.coordinator@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sharon L. Gardner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birte Wistinghausen</last_name>
      <phone>212-824-7309</phone>
      <email>CCTO@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Birte Wistinghausen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Aledo</last_name>
      <phone>212-746-1848</phone>
    </contact>
    <investigator>
      <last_name>Alexander Aledo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey R. Andolina</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey R. Andolina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura E. Hogan</last_name>
      <phone>800-862-2215</phone>
    </contact>
    <investigator>
      <last_name>Laura E. Hogan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip M. Monteleone</last_name>
      <phone>315-464-5476</phone>
    </contact>
    <investigator>
      <last_name>Philip M. Monteleone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica C. Hochberg</last_name>
      <phone>914-594-3794</phone>
    </contact>
    <investigator>
      <last_name>Jessica C. Hochberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital-Memorial Campus</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas J. Scothorn</last_name>
      <phone>828-213-4150</phone>
    </contact>
    <investigator>
      <last_name>Douglas J. Scothorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart H. Gold</last_name>
      <phone>877-668-0683</phone>
      <email>cancerclinicaltrials@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart H. Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel A. Kaplan</last_name>
      <phone>704-355-2884</phone>
    </contact>
    <investigator>
      <last_name>Joel A. Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica A. Bell</last_name>
      <phone>704-384-5369</phone>
    </contact>
    <investigator>
      <last_name>Jessica A. Bell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan G. Kreissman</last_name>
      <phone>888-275-3853</phone>
    </contact>
    <investigator>
      <last_name>Susan G. Kreissman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea R. Whitfield</last_name>
      <phone>252-744-2391</phone>
    </contact>
    <investigator>
      <last_name>Andrea R. Whitfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas B. Russell</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <investigator>
      <last_name>Thomas B. Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Broadway Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel O. Anim</last_name>
      <phone>800-437-4010</phone>
    </contact>
    <investigator>
      <last_name>Samuel O. Anim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Kuerbitz</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Steven J. Kuerbitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen M. O'Brien</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Maureen M. O'Brien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John J. Letterio</last_name>
      <phone>216-844-5437</phone>
    </contact>
    <investigator>
      <last_name>John J. Letterio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aron Flagg</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Aron Flagg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A. Ranalli</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Mark A. Ranalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman A. El-Sheikh</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Ayman A. El-Sheikh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Toledo Hospital/Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie L. Dargart</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jamie L. Dargart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at Saint Francis</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory B. Kirkpatrick</last_name>
      <phone>918-494-2200</phone>
    </contact>
    <investigator>
      <last_name>Gregory B. Kirkpatrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice F. Olson</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Janice F. Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bill H. Chang</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Bill H. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital-Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia A. Boateng</last_name>
      <phone>734-712-3671</phone>
    </contact>
    <investigator>
      <last_name>Lydia A. Boateng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jagadeesh Ramdas</last_name>
      <phone>570-271-5251</phone>
      <email>HemonCCTrials@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Jagadeesh Ramdas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa M. McGregor</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Lisa M. McGregor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan R. Rheingold</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Susan R. Rheingold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory E. Halligan</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Gregory E. Halligan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur K. Ritchey</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Arthur K. Ritchey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer J. Greene Welch</last_name>
      <phone>401-444-1488</phone>
    </contact>
    <investigator>
      <last_name>Jennifer J. Greene Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline M. Kraveka</last_name>
      <phone>843-792-9321</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline M. Kraveka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart L. Cramer</last_name>
      <phone>803-434-3680</phone>
    </contact>
    <investigator>
      <last_name>Stuart L. Cramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichole L. Bryant</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Nichole L. Bryant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Cancer Treatment Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayelyn J. Wagner</last_name>
      <phone>605-328-1367</phone>
    </contact>
    <investigator>
      <last_name>Kayelyn J. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T C Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoo G. Bhakta</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Manoo G. Bhakta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray C. Pais</last_name>
      <phone>865-541-8266</phone>
    </contact>
    <investigator>
      <last_name>Ray C. Pais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at TriStar Centennial</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haydar A. Frangoul</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Haydar A. Frangoul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra L. Friedman</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Debra L. Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center-Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy C. Fowler</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Amy C. Fowler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nkechi I. Mba</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Nkechi I. Mba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanton C. Goldman</last_name>
      <phone>972-566-5588</phone>
    </contact>
    <investigator>
      <last_name>Stanton C. Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamra L. Slone</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>Tamra L. Slone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Paso Children's Hospital</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa L. Hartman</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Lisa L. Hartman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth M. Heym</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth M. Heym</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen R. Rabin</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Karen R. Rabin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael E. Rytting</last_name>
      <phone>877-312-3961</phone>
    </contact>
    <investigator>
      <last_name>Michael E. Rytting</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kishor M. Bhende</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Kishor M. Bhende</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad M. Al-Rahawan</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Mohamad M. Al-Rahawan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vannie Cook Children's Clinic</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan C. Bernini</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Juan C. Bernini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy C. Griffin</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Timothy C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod K. Gidvani-Diaz</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Vinod K. Gidvani-Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie R. Langevin</last_name>
      <phone>210-450-3800</phone>
      <email>CTO@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie R. Langevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy H. Grayson</last_name>
      <phone>254-724-5407</phone>
    </contact>
    <investigator>
      <last_name>Guy H. Grayson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip E. Barnette</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Phillip E. Barnette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan C. Homans</last_name>
      <phone>802-656-8990</phone>
    </contact>
    <investigator>
      <last_name>Alan C. Homans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William C. Petersen</last_name>
      <phone>434-243-6322</phone>
      <email>JME3D@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>William C. Petersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall A. Schorin</last_name>
      <phone>703-208-6650</phone>
      <email>Stephanie.VanBebber@inova.org</email>
    </contact>
    <investigator>
      <last_name>Marshall A. Schorin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital-King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric J. Lowe</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Eric J. Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center - Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina M. Wiedl</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Christina M. Wiedl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic Children's Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy M. Atkinson</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Mandy M. Atkinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas S. Hawkins</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Douglas S. Hawkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy L. Felgenhauer</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Judy L. Felgenhauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert G. Irwin</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Robert G. Irwin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa A. Forouhar</last_name>
      <phone>253-968-0129</phone>
      <email>mamcdci@amedd.army.mil</email>
    </contact>
    <investigator>
      <last_name>Melissa A. Forouhar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley E. Meyer</last_name>
      <phone>304-388-9944</phone>
    </contact>
    <investigator>
      <last_name>Ashley E. Meyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan R. Paul</last_name>
      <phone>304-293-7374</phone>
      <email>cancertrialsinfo@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephan R. Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine A. Long</last_name>
      <phone>920-433-8889</phone>
      <email>Christy.Gilchrist@hshs.org</email>
    </contact>
    <investigator>
      <last_name>Catherine A. Long</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth B. De Santes</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Kenneth B. De Santes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. McManus</last_name>
      <phone>715-389-4457</phone>
    </contact>
    <investigator>
      <last_name>Michael J. McManus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard L. Tower</last_name>
      <phone>414-955-4727</phone>
      <email>MACCCTO@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Richard L. Tower</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Children's Hospital</name>
      <address>
        <city>Hunter Regional Mail Centre</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth L. Hesketh</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth L. Hesketh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital-Brisbane</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Irving</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Helen Irving</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital-Adelaide</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria L. Kirby</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Maria L. Kirby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center-Clayton Campus</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J. Wood</last_name>
      <phone>(03) 9928 8111</phone>
    </contact>
    <investigator>
      <last_name>Paul J. Wood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise M. Mechinaud</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Francoise M. Mechinaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne B. Phillips</last_name>
      <phone>(08) 9340 8222</phone>
      <email>catherine.cole@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Marianne B. Phillips</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas R. Strother</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Douglas R. Strother</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah J. McKillop</last_name>
      <phone>780-407-6615</phone>
      <email>val.taylor@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Sarah J. McKillop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya R. Brown</last_name>
      <phone>866-561-1026</phone>
      <email>CIO_Web@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Tanya R. Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Janeway Child Health Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Anne B. Goodyear</last_name>
      <phone>866-722-1126</phone>
    </contact>
    <investigator>
      <last_name>Lisa Anne B. Goodyear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrad V. Fernandez</last_name>
      <phone>902-470-6767</phone>
    </contact>
    <investigator>
      <last_name>Conrad V. Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol A. Portwine</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Carol A. Portwine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana P. Silva</last_name>
      <phone>613-549-6666</phone>
      <email>cc-clinicaltrials@kgh.kari.net</email>
    </contact>
    <investigator>
      <last_name>Mariana P. Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shayna M. Zelcer</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Shayna M. Zelcer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna L. Johnston</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Donna L. Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Hitzler</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>2027</phone_ext>
      <email>jason.mcguire@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Johann Hitzler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Montreal Children's Hospital of the MUHC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon B. Abish</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Sharon B. Abish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Mpofu</last_name>
      <phone>306-655-2914</phone>
    </contact>
    <investigator>
      <last_name>Christopher Mpofu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Co Dublin</state>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1145</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lochie R. Teague</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Lochie R. Teague</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lochie R. Teague</last_name>
      <phone>03 364 0640</phone>
    </contact>
    <investigator>
      <last_name>Lochie R. Teague</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis A. Clavell</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Luis A. Clavell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis A. Clavell</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Luis A. Clavell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group - Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Swiss Pediatric Oncology Group - Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Ireland</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

